Cognition Therapeutics Inc
CGTX
Company Profile
Business description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Contact
2500 Westchester Avenue
PurchaseNY10577
USAT: +1 412 481-2210
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,311.50 | 23.60 | 0.28% |
| CAC 40 | 7,555.87 | 17.89 | -0.24% |
| DAX 40 | 22,425.83 | 154.16 | 0.69% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,463.46 | 46.12 | 0.55% |
| HKSE | 22,056.10 | 47.99 | 0.22% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 35,915.78 | 75.79 | 0.21% |
| NZX 50 Index | 11,912.94 | 112.51 | -0.94% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,097.90 | 27.30 | 0.34% |
| SSE Composite Index | 3,283.97 | 2.68 | -0.08% |